Sirolimus, the first mTOR inhibitor.
Sánchez-Plumed
J A
JA
Nephrology Service, Hospital La Fe, Valencia. jasanchezp@senefro.org
González Molina
M
M
Alonso
A
A
Arias
M
M
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D050197:Atherosclerosis / Q000517:prevention & control; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002455:Cell Division / Q000187:drug effects; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000009:adverse effects; D006084:Graft Rejection / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D007674:Kidney Diseases / Q000139:chemically induced; D016030:Kidney Transplantation / Q000276:immunology; D016131:Lymphocyte Subsets / Q000166:cytology / Q000187:drug effects; D051379:Mice; D015337:Multicenter Studies as Topic; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D020123:Sirolimus / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D014945:Wound Healing / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus